Another clinical trial of sequential CD22/CD19 CAR T-cell therapy aimed to evaluate the efficacy and safety in 14 patients with R/R aggressive B-cell lymphoma involving the gastrointestinal (GI) tract. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.